C11蛋氨酸PET(MET-PET)显像检测胶质母细胞瘤术后残留病灶及对放化疗的反应
这项前瞻性显像研究纳入新诊断胶质母细胞瘤患者,在手术切除后3天内及放化疗结束后4周各行一次MET-PET,评估其检测放化疗后代谢变化及分子标志物预测代谢反应幅度的价值。结果显示术后有残留MET高摄取且完成放化疗后MET-PET的患者(n=10)SUVmax平均下降40%、SUVmean下降35%、SUVvolume下降64%,而MRI T2/FLAIR信号视觉评估无一例下降超过25%;ΔSUVmax、ΔSUVmean、ΔSUVvolume与MGMT启动子甲基化状态相关(P=.01)。
要点
- 术后有残留MET高摄取并完成放化疗后MET-PET的10例患者,SUVmax平均下降40%、SUVmean下降35%、SUVvolume下降64%。
- 对比增强MRI的T2加权图像视觉评估无一例显示异常T2/FLAIR信号下降超过25%。
- ΔSUVmax、ΔSUVmean、ΔSUVvolume与MGMT启动子甲基化状态相关(P=.01),与EGFR或c-MET扩增状态无关。
核心结论
- MET-PET显示放化疗后1个月代谢信号较术后即刻显著下降,即使T2/FLAIR变化很小。
- MGMT启动子甲基化状态进一步预测不同的代谢反应。
- MET-PET可能是用于勾画放疗靶区和评估反应的有用工具。
研究设计与样本
- 前瞻性显像研究,纳入新诊断胶质母细胞瘤并接受标准放化疗的患者。
- MET-PET在手术切除后3天内进行,并在放化疗完成后4周再次进行。
- 每次MET-PET扫描前后2周内进行近同期的对比增强MRI。
- 共18例患者接受基线术后MET-PET显像,其中14例接受了放化疗后MET-PET显像。
主要发现
- 术后即刻MET-PET显示有残留MET高摄取并接受放化疗后MET-PET显像的患者(n=10)中,平均ΔSUVmax为-40%(范围-100%至0%),平均ΔSUVmean为-35%(范围-100%至0%),平均ΔSUVvolume为-64%(范围-100%至0%)。
- 以SUVmax计算的Δtumor/brain参考值为-40%(范围-100%至0%),以SUVmean计算为-35%(范围-100%至0%)。
- 对比增强MRI的T2加权图像视觉评估无一例显示异常T2/FLAIR信号下降超过25%。
- ΔSUVmax、ΔSUVmean、ΔSUVvolume与MGMT启动子甲基化状态相关(P=.01),与表皮生长因子受体或c-MET扩增状态无关。
- 所有患者均为IDH-1野生型。
关键数值与推荐
- 术后有残留MET高摄取并完成放化疗后MET-PET的10例患者中,平均ΔSUVmax为-40%(范围-100%至0%)。
- 同一组患者中,平均ΔSUVmean为-35%(范围-100%至0%),平均ΔSUVvolume为-64%(范围-100%至0%)。
- ΔSUVmax、ΔSUVmean、ΔSUVvolume与MGMT启动子甲基化状态相关(P=.01)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Response criteria of glioblastoma after chemoradiation do not account for metabolic changes that occur after treatment. The purpose of this study is to evaluate the utility of positron emission tomography (PET) imaging with C11 methionine (MET) (MET-PET) for detecting changes that occur after chemoradiation therapy and the value of molecular biomarkers for predicting the magnitude of metabolic response. METHODS AND MATERIALS: Patients with newly diagnosed glioblastoma undergoing standard chemoradiation treatment were enrolled in this prospective imaging study, with MET-PET scan performed within 3 days after surgical resection and again at 4 weeks after completion of chemoradiation. Near contemporaneous contrast-enhanced magnetic resonance imaging was performed within 2 weeks of each MET-PET scan. MET-PET imaging was analyzed for maximum standardized uptake value (SUV), SUVmean, and SUVvolume on a multimodality workstation. RESULTS: A total of 18 patients underwent baseline postoperative MET-PET imaging, 14 of whom underwent postchemoradiation MET-PET imaging. Among those who showed residual MET-avid disease on immediate postoperative MET-PET scans and underwent postchemoradiation MET-PET imaging (n = 10), mean ΔSUVmax was -40% (range -100% to 0%), mean ΔSUVmean was -35% (range -100% to 0%), and mean ΔSUV volume was -64% (range -100% to 0%). The Δtumor/brain reference was -40% (range -100% to 0%) using SUVmax and -35% (range -100% to 0%) using SUVmean. In contrast, none of the T2-weighted images on contrast-enhanced magnetic resonance imaging showed a >25% reduction in abnormal T2/fluid-attenuated inversion recovery signal on visual assessment. ΔSUVmax, ΔSUVmean, and ΔSUVvolume correlated with O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status (P = .01), but not with epidermal growth factor receptor or c-MET amplification status. All patients were IDH-1 wildtype. CONCLUSIONS: MET-PET scanning shows a significant decrease in metabolic signal at 1 month after chemoradiation compared with the immediate postoperative period, even when T2/fluid-attenuated inversion recovery changed little. MGMT promoter methylation status further predicts differential metabolic responses. MET-PET may be a useful tool for delineation of radiation targets and assessment of response.
引用
- Wang Y, Rapalino O, Heidari P, et al. C11 Methionine PET (MET-PET) Imaging of Glioblastoma for Detecting Postoperative Residual Disease and Response to Chemoradiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 29913253. doi:10.1016/j.ijrobp.2018.06.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。